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OBJECTIVE: Recent studies have shown that circulating microRNAs might be useful, novel biomarkers for the
diagnosis of acute myocardial infarction. The aims of this study were to evaluate the expression of cardiac-
specific miRNAs (miR-1, -133a, -208b, and -499) in patients with acute myocardial infarction and to compare the
diagnostic values of these miRNAs with that of cardiac troponin T.
METHODS: Sixty-seven plasma samples obtained from patients with acute myocardial infarction and 32 plasma
specimens collected from healthy volunteers were analyzed in this study. The levels of cardiac-specific miRNAs
(miR-1, -133a, -208b, and -499) were measured by quantitative reverse transcription-polymerase chain reaction,
and the concentrations of plasma cardiac troponin T were measured using electrochemiluminescence-based
methods and an Elecsys 2010 Immunoassay Analyzer.
RESULTS: The levels of plasma miR-1, -133a, -208b, and -499 were significantly higher in acute myocardial
infarction patients (all p,0.001) than in healthy volunteers. The expression of the cardiac-specific miRNAs in
acute myocardial infarction patients decreased to close to the baseline levels at the time of hospital discharge
(all p.0.05). There were no correlations between the levels of the four circulating miRNAs and the clinical
characteristics of the study population (all p.0.05). Furthermore, receiver operating characteristic curve
analyses showed that the four plasma miRNAs were not superior to cardiac troponin T for the diagnosis of acute
myocardial infarction (all p.0.05).
CONCLUSION: Our results demonstrate that circulating miR-1, -133a, -208b, and -499 may be useful biomarkers
in acute myocardial infarction patients but that these miRNAs are not superior to cardiac troponin T for the
diagnosis of acute myocardial infarction.
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& INTRODUCTION
Acute myocardial infarction (AMI) is a leading cause of
morbidity and mortality worldwide, and approximately three
to four million people are estimated to suffer from AMI each
year (1). Early reperfusion can reduce the mortality rate of
AMI (2); therefore, the timely diagnosis of AMI is critical.
The circulating levels of cardiac troponins (cTns) are
considered the ‘‘gold standard’’ for the early diagnosis of
AMI because cTns are both highly specific and sensitive for
cardiac injury (3). However, early studies have reported that
cTn concentrations are also elevated in patients with end-
stage renal disease (ESRD) and that these molecules might
serve as biomarkers for renal failure (4,5). Therefore, it is
essential to explore new biomarkers with greater specificity
for AMI.
MicroRNAs (miRNAs) are a class of endogenous, non-
coding single-stranded small RNAs of 19 to 25 nucleotides
in length (6) that can regulate gene expression and play
critical roles in various pathophysiological processes (7,8).
miRNAs generally suppress gene expression by inhibiting
mRNA translation or inducing mRNA degradation. Each
miRNA can regulate several distinct target mRNAs, and
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conversely, single mRNAs can be targeted by several
distinct miRNAs (9). Thus, the overall effects of miRNA-
associated regulation can be very complex. To date, over 700
human miRNAs have been cloned or sequenced (10,11).
Although the biological and pathological functions of
miRNAs are not completely understood, it is clear that
many miRNAs demonstrate tissue- or cell-specific distribu-
tions and play important roles in cell and/or tissue
functions under various conditions (12,13). Furthermore,
recent studies have demonstrated that miRNAs can be
detected in the peripheral blood or plasma, and that the
levels of circulating miRNAs are characteristically altered in
individuals with various pathological conditions, indicating
that circulating miRNAs may be useful diagnostic biomar-
kers for specific diseases (14,15).
Interestingly, miRNAs are present in the blood and/or
plasma in a strikingly stable form that withstands even
repeated freeze/thaw cycles and is resistant to RNase
degradation (16). Although the mechanisms by which
miRNAs are released into the circulation are not clear, the
levels of several miRNAs in the blood and/or plasma were
observed to be altered during AMI. This result suggests that
circulating myocardial-derived miRNAs, such as miR-1,
133a, -208b, and -499, might be good biomarkers for the
diagnosis of AMI (17-25). However, the suitability of these
four circulating miRNAs for the diagnosis of AMI in
humans remains somewhat controversial. For example,
Wang et al. found that circulating miR-208b was a good
biomarker for the diagnosis of AMI, whereas circulating
miR-1, -133a, and -499 were not good biomarkers because of
their low sensitivities (17). Meanwhile, Alessandra et al.
have reported that circulating miR-208b could not be
detected in AMI patients and that circulating miR-1, -133a,
and -499 are novel biomarkers for the diagnosis of AMI (25).
Therefore, the objectives of the current work were to
measure the levels of circulating miRNAs (miR-1, -133a,
-208b, and -499) and the concentration of cardiac troponin T
(cTnT) in AMI patients at two medical centers. Additionally,
we analyzed the utility of these four miRNAs as novel
biomarkers for the early diagnosis of AMI and compared
their diagnostic values with that of cTnT.
& MATERIALS AND METHODS
Clinical specimens
Sixty-seven patients diagnosed with AMI were enrolled
in this study at the First Affiliated Hospital of Sun Yat-Sen
University (Guangzhou, China) and the First Affiliated
Hospital of NanHua University (Hengyang, China) between
October 2010 and March 2011. The inclusion criteria for
patients with AMI were based on the redefined guidelines
from the most recent standard definition of MI (26). Briefly,
AMI was diagnosed in patients with increased cTnT or
creatine kinase-MB (CK-MB) levels combined with chest
pain lasting .30 minutes and electrocardiogram (ECG)
findings such as new pathological Q waves or ST-segment
elevation or depression. Patients were excluded if they had
received intravenous thrombolytic or anticoagulant treat-
ment before the initial blood samples were acquired. Forty-
four patients (66%) experienced ST-segment elevation
myocardial infarction (STEMI), whereas 23 (34%) experi-
enced non-ST-segment elevation myocardial infarction
(NSTEMI). Thirty-nine patients (58%) were treated with
percutaneous coronary intervention (PCI), whereas 28 (42%)
were treated with thrombolysis. Thirty-two age- and sex-
matched samples from healthy volunteers (no history of
cardiovascular disease and normal electrocardiographic
findings) were used as controls. The study protocol was
approved by the Ethics Committees of Sun Yat-Sen
University and NanHua University, and written informed
consent was obtained from all participants.
Plasma collection and storage
Venous blood samples (3 mL) were collected from AMI
patients on Day 1 (n = 67) within 12 h of the onset of
symptoms (4.6¡2.9 h) and on Day 14 (n = 18) and from
healthy volunteers using K2-EDTA-coated tubes. Plasma
was isolated by centrifugation at 1,000 g for 10 minutes at
4 C˚, followed by centrifugation of the supernatant at 14,000
g for 15 minutes at 4 C˚. The plasma was transferred into
RNase/DNase-free tubes and stored at -80 C˚ until RNA
extraction.
RNA isolation
Total RNA was isolated from plasma using the TRIzol
LSH reagent (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instructions and dissolved in 10 mL of
diethylpyrocarbonate (DEPC)-treated water. The concentra-
tion and quality of the RNA samples were determined using
a BioPhotometer (Eppendorf).
Quantitative reverse transcription-polymerase
chain reaction (qRT-PCR)
The Bulge-LoopTM miRNA qRT-PCR Primer Set (RiboBio
Co, Guangzhou, China) was used to detect and quantify the
expression of mature microRNAs (miR-1, -133a, -208b, and
-499) according to the manufacturer’s instructions; a
Caenorhabditis elegans microRNA (cel-miR-39) was used as
the internal control (14). Total RNA (0.5 mg) from each sample
was reverse transcribed using microRNA-specific primers
and M-MLV reverse transcriptase (Promega, Madison, WI,
USA). The reaction was carried out for 60 min at 42 C˚,
followed by 10 min at 70 C˚, and the resulting cDNA was
stored at -20 C˚ until use.
The qRT-PCR reactions were performed on the PRISM
7900HT sequence detection system (Applied Biosystems,
Carlsbad, CA, USA) in 20-mL reactions containing 2 mL of
reverse transcription product, 2 mL of PCR forward primer
(5 mM), 2 mL of Universal Adaptor PCR Primer (5 mM), 9 mL
of Platinum SYBR Green qPCR SuperMix-UDG reagent
(Invitrogen, Carlsbad, CA, USA), and 5 mL of ddH2O. The
reactions were incubated at 95 C˚ for 2 min, followed by 40
cycles of 95 C˚ for 15 s, 60 C˚ for 30 s and 95 C˚ for 15 s. The
samples were then heated from 60 C˚ to 95 C˚ to obtain
melting curves. Reactions containing either no reverse
transcriptase or no template were used as negative controls,
and all assays were performed in triplicate. These proce-
dures were performed by an investigator (L.L.) blinded to
the clinical characteristics of the patients. The threshold
cycle (Ct) was defined as the fractional cycle number at
which the fluorescence exceeded the given threshold, and
the relative expression values of the microRNAs were
calculated using the 22DDCt method (27).
cTnT determination
The levels of plasma cTnT were determined using electro-
chemiluminescence-based methods with the Elecsys 2010
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Immunoassay Analyzer (Roche Diagnostics, Switzerland)
according to the manufacturer’s protocol.
Statistical analysis
The Statistical Package for Social Sciences, version 16.0
(SPSS, Inc., Chicago, IL, USA), was used for the statistical
analysis. All data are presented as the mean¡standard
deviation unless otherwise noted. The significance of the
differences in clinical characteristics between AMI patients
and controls was tested using Student’s t-test or Fisher’s
exact test. The Mann-Whitney test was conducted to
compare the expression of microRNAs between the AMI
patients and controls. The microRNA levels measured in
each AMI patient at the two time points were compared
using the Wilcoxon signed rank test. Receiver operating
characteristic (ROC) curves were established to discriminate
between AMI patients and controls with Stata version 10.0
and were compared using the chi-square test. All p-values
were two-tailed, and p,0.05 was considered statistically
significant.
& RESULTS
Clinical characteristics of the study population
In the present study, we enrolled 67 patients with AMI and
32 controls. The clinical characteristics of each group are listed
in Table 1. The mean age of the AMI patients was 63.84¡11.17
years, and the mean age of the controls was 61.75¡9.58 years
(p= 0.332). Both groups were predominantly male (52/67 in
the AMI group and 22/32 in the control group; p= 0.343). The
mean cTnT level at admission in AMI patients was 1.30¡1.06
ng/mL, which was significantly higher than the mean cTnT
level in the control group (p,0.001). There were no significant
differences in any other clinical characteristics between the
AMI and control groups.
Circulating cardiac-associated microRNA levels were
elevated in AMI patients
To determine whether the circulating cardiac-associated
microRNAs were associated with the onset of AMI, we
investigated the plasma levels of four microRNAs (miR-1,
-133a, -208b, and -499) in AMI patients and controls. As
shown in Figure 1, the plasma concentrations of miR-1,
-133a, -208b, and -499 were all markedly elevated in AMI
patients relative to controls (p,0.001). Furthermore, there
were no significant differences in the levels of these four
miRNAs between STEMI and NSTEMI patients (all p.0.05,
Figure 2A), and there were also no significant differences
between the PCI and thrombolysis groups (all p.0.05,
Figure 2B).
We also measured the levels of the four miRNAs in
plasma from AMI patients at the time of hospital discharge
(n = 18, patients who lived more than 14 days and agreed to
take part in this part of the study), and we found that the
miRNA levels had decreased to baseline levels, i.e., they
were not significantly different from the levels in the
controls (p.0.05) (Figure 3).
Circulating cardiac-associated microRNAs as
potential predictors of AMI
To evaluate the predictive power of circulating cardiac-
associated microRNAs for AMI, we performed ROC analysis
for 67 patients with AMI. As shown in Figure 4, the areas
under the ROC curves (AUCs) for miR-1, miR-133a, miR-
208b, and miR-499 were 0.8265 (95% confidence interval,
0.7441-0.9088), 0.9468 (95% confidence interval, 0.9057-0.9879),
0.8899 (95% confidence interval, 0.8259-0.9540), and 0.8841
(95% confidence interval, 0.8187-0.9495), respectively. The
AUC measured for cTnT was 0.9820 (95% confidence interval,
0.9289-0.9975). These results demonstrate that the four
miRNAs had marked sensitivity and specificity for AMI.
However, none of the four miRNAs tested was superior to
cTnT for the diagnosis of AMI (all p.0.05).
& DISCUSSION
In our present study, we found that the levels of miRNA-1, -
133a, -208b, and -499 were significantly increased in patients
after AMI relative to the levels in healthy volunteers, and our
data indicated that the elevated expression of these four
miRNAs was coincident with the progression of the AMI. As
we now know, in the early stages of AMI, pathological
changes such as myocardial ischemia, hypoxia, edema, and
necrosis occur rapidly, followed by the release of necrotic
products, such as cardiac troponins (cTns), creatine kinase
(CK) and brain natriuretic peptide (BNP), into the blood-
stream. These established biomarkers can be useful for the
early diagnosis of AMI. The results of the present work
suggest that miRNA-1, -133a, -208b, and -499 might leak out
of the necrotic myocardium and into the circulation during
the early stages of AMI, and the levels of these miRNAs
would thus become elevated as the AMI progresses; therefore,
these four circulating miRNAs might be useful biomarkers for
the diagnosis of AMI.
AMI is a leading cause of death in both developed and
developing countries, and the mortality rate of this disease
can be reduced by early diagnosis. Established biomarkers
such as cTnT, CK-MB, BNP and C-reactive protein (CRP)
play critical roles in the diagnosis of AMI (3,28,29).
According to the recent redefinition of myocardial infarc-
tion by the ESC/ACC (European Society of Cardiology/
American College of Cardiology) Consensus group, troponins
are more sensitive and specific measures of myocyte necrosis
with respect to AMI diagnosis than CK-MB, BNP, and CRP
(30-32). Nevertheless, cTns have several weaknesses, includ-
ing incomplete specificity for AMI. For example, some studies
have reported that cTn levels were elevated in ESRD patients
and that cTns might serve as prognostic biomarkers in RF
patients (4,5). Therefore, it is important to continue the search
for new biomarkers with higher sensitivity and specificity for
the early diagnosis of AMI.
Several recent studies have reported that miRNAs exhibit
tissue- and cell-specific characteristics under various conditions;
Table 1 - Clinical characteristics of the study population.
Characteristics Control (n = 32) AMI (n= 67) p-value
Age (years) 61.75¡9.58 63.84¡11.17 0.332
Male/Female (n/n) 22/10 52/15 0.343
Currently smoking, n (%) 13 (40.63) 32 (47.76) 0.505
Diabetes mellitus, n (%) 5 (15.63) 13 (19.40) 0.649
Hypertension, n (%) 15 (46.88) 38 (56.72) 0.358
Hyperlipidemia, n (%) 14 (43.75) 36 (53.75) 0.353
Systolic blood pressure (mmHg) 125.56¡12.52 129.66¡15.35 0.203
Diastolic blood pressure (mmHg) 79.75¡6.81 81.57¡9.76 0.210
Cardiac troponin T (ng/mL) 0.03¡0.02 1.30¡1.06 ,0.001
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additionally, miRNAs can be released into the circulation,
where they persist in a stable form (12,16,17). Several
consecutive reports have shown that the levels of circulating,
cardiac-specific miRNAs were altered in conjunction with the
progression of cardiovascular diseases; therefore, these
miRNAs might be promising novel biomarkers for the
diagnosis of AMI.
The findings from our present study are consistent with
those reported in recent articles, indicating that levels of the
circulating miRNAs miRNA-1, -133a, -208b, and -499 were
increased during AMI and were significantly higher than
those in healthy volunteers. The levels of the four circulating
miRNAs decreased to normal levels at the time of hospital
discharge. We also analyzed the concentration of cTnT
during AMI. cTns are established biomarkers for the
diagnosis of AMI and reflect infarct size. Compared with
cTnI, cTnT is more specific and sensitive for the diagnosis of
AMI (33-35). Therefore, we selected cTnT as a benchmark
for comparison with circulating miRNAs in the present
study.
We performed ROC curve analyses to determine the
diagnostic values of the four circulating miRNAs and to
compare them with cTnT. The results of these analyses
indicated that circulating miR-1, -133a, -208b, and -499 were
specific and sensitive for the early diagnosis of AMI and are
promising novel biomarkers for AMI. Although there were
positive relationships between the four circulating miRNAs
and cTnT within 12 hours of the onset of symptoms (Day 1),
none of the four circulating miRNAs (miR-1, -133a, -208b, and
-499) was superior to cTnT for the early diagnosis of AMI.
According to these results, cTnT seems to be more
sensitive and specific than any of the four circulating
miRNAs in patients with AMI. We hypothesized that cTnT
might be released from necrotic myocardium at the time of
the AMI in patients prior to the onset of chest pain. Previous
studies have demonstrated that cTnT is primarily bound to
myofibrils and that miRNAs are primarily bound to
cytosolic protein complexes. We hypothesized that these
differences might affect the patterns of cTnT and miRNA
release during the progression of myocardial necrosis.
Figure 1 - Levels of the four circulating miRNAs in AMI patients. The plasma levels of miR-1 (A), miR-133a (B), miR-208b (C), and miR-499
(D) were significantly increased in AMI patients (n=67) relative to the controls (n =32) (p,0.001).
Figure 2 - Stratified analysis of the levels of the four circulating miRNAs in AMI patients. (A) Circulating miR-1, -133a, -208b, and -499
levels in STEMI and NSTEMI patients; (B) circulating miR-1, -133a, -208b, and -499 levels in AMI patients treated with PCI or
thrombolysis.
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Our present study provides clinical evidence to support the
use of circulating miR-1, -133a, -208b, and -499 as biomarkers
for AMI. However, our work has some limitations, including
the small sample size. Therefore, additional studies with
larger cohorts of healthy volunteers and patients are needed
to definitively demonstrate the diagnostic value of the four
circulating miRNAs as practical biomarkers in comparison
with other markers and to reduce the rate of false-positive
Figure 3 - Alteration of the plasma miRNA levels in AMI patients. (A-D) The levels of miR-1, -133a, -208b, and -499 were markedly
increased in plasma samples gathered within 12 hours of the onset of AMI (Day 1). At the time of hospital discharge (Day 14), the levels
of these four miRNAs had returned to levels similar to those in the control subjects (n=32 control subjects, n = 67 AMI patients at Day 1,
n =18 AMI patients at Day 14). The values shown represent the fold change of each miRNA in AMI patients relative to control subjects.
The results are presented as the mean ¡ standard deviation. *p,0.001 vs. control.
Figure 4 - Comparisons of the sensitivity and specificity of the four plasma miRNAs and cTnT for the diagnosis of AMI. Receiver
operating characteristic (ROC) curves were constructed to evaluate the diagnostic values of miR-1, -133a, -208b, and -499 for AMI
patients in comparison with cTnT. AUC, area under the ROC curve.
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results. Additionally, the diagnostic values of the circulating
miRNAs need to be investigated in further studies involving
ESRD patients with AMI and in AMI patients without ESRD.
In conclusion, this study verified the diagnostic value of
four circulating miRNAs (miR-1, -133a, -208b, and -499) in
the early stage of AMI and compared them with the
established biomarker cTnT. We demonstrated that miR-1,
-133a, -208b, and -499 might serve as novel biomarkers for
the diagnosis of AMI; however, the diagnostic values of
these circulating miRNAs were not superior to that of cTnT.
Because the cTnT concentration is also increased in ESRD
patients, we propose that cTnT and miRNA analyses could
be combined to enhance the specificity of AMI diagnosis.
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